XTLB Stock Overview
A biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases in Israel. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
XTL Biopharmaceuticals Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪0.067 |
| 52 Week High | ₪0.17 |
| 52 Week Low | ₪0.031 |
| Beta | 1.0 |
| 11 Month Change | -23.86% |
| 3 Month Change | -37.96% |
| 1 Year Change | 91.43% |
| 33 Year Change | -34.95% |
| 5 Year Change | 36.73% |
| Change since IPO | -99.72% |
Recent News & Updates
Shareholder Returns
| XTLB | IL Biotechs | IL Market | |
|---|---|---|---|
| 7D | 1.5% | -1.1% | 1.9% |
| 1Y | 91.4% | -7.3% | 26.9% |
Return vs Industry: XTLB exceeded the IL Biotechs industry which returned -7.1% over the past year.
Return vs Market: XTLB exceeded the IL Market which returned 28% over the past year.
Price Volatility
| XTLB volatility | |
|---|---|
| XTLB Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in IL Market | 7.4% |
| 10% least volatile stocks in IL Market | 2.8% |
Stable Share Price: XTLB's share price has been volatile over the past 3 months compared to the IL market.
Volatility Over Time: XTLB's weekly volatility has decreased from 23% to 10% over the past year, but is still higher than 75% of IL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | n/a | Shlomo Shalev | www.xtlbio.com |
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications.
XTL Biopharmaceuticals Ltd. Fundamentals Summary
| XTLB fundamental statistics | |
|---|---|
| Market cap | ₪84.04m |
| Earnings (TTM) | -₪1.42m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-59.4x
P/E RatioIs XTLB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XTLB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$378.00k |
| Earnings | -US$378.00k |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0003 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did XTLB perform over the long term?
See historical performance and comparison